Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recommendations for the treatment of invasive fungal infection caused by filamentous fungi in the hematological patient.
Barberán J, Mensa J, Llamas JC, Ramos IJ, Ruiz JC, Marín JR, Tello PB, Massana MB, Vidal JB, Viñas JM, Huelva FJ, Pons EC, Mediavilla JD, Morfa ML, Barrigón FE, Avellán PF, López SG, García CG, Maraver DH, Guía AL, Jiménez JL, Chacón EM, Rubio MO, Oteyza JP, Ramírez GR, Contreras RR, Barbero AR, Tarrats MR, Félix DR, Godoy PS, Salinas AS, Alonso MA, Torroba Jde L, Ferreiras DV, López LV, García JM, Perea JR, Moreno RC, Cáncer RC, Abete JF, Rodríguez JG, Gómez JG, Pedrosa EG, Baranda JM, García FJ, Camps IR, Lleti MS, Cisneros Jde L; Spanish Society of Chemotherapy. Barberán J, et al. Among authors: abete jf. Rev Esp Quimioter. 2011 Dec;24(4):263-70. Rev Esp Quimioter. 2011. PMID: 22173196 Free article. Review.
[Intraabdominal infection in inmunodepressed patients].
Abete JF, Martín-Dávila P. Abete JF, et al. Enferm Infecc Microbiol Clin. 2010 Sep;28 Suppl 2:11-7. doi: 10.1016/S0213-005X(10)70025-2. Enferm Infecc Microbiol Clin. 2010. PMID: 21130925 Review. Spanish.
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group. Griffith DE, et al. Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC. Am J Respir Crit Care Med. 2018. PMID: 30216086 Clinical Trial.
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W; SOLO I and SOLO II investigators. Corey GR, et al. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01919-17. doi: 10.1128/AAC.01919-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29358292 Free PMC article. Clinical Trial.
Single-dose oritavancin in the treatment of acute bacterial skin infections.
Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W; SOLO I Investigators. Corey GR, et al. N Engl J Med. 2014 Jun 5;370(23):2180-90. doi: 10.1056/NEJMoa1310422. N Engl J Med. 2014. PMID: 24897083 Free article. Clinical Trial.